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Abstract 
 
Vetsuisse Faculty, University of Zurich (2015) 
 
Marco Dominic Geisseler 
 
Institute of Virology, email@vetvir.uzh.ch 
 
Geno- and seroprevalence of Felis domesticus Papillomavirus type 2 (FdPV2) in 
healthy cats 
 
Papillomaviruses can cause proliferative skin lesions ranging from benign 
hyperplasia to squamous cell carcinoma (SCC). However, asymptomatic infection is 
also possible. Several groups have detected FdPV2 DNA in association with feline 
Bowenoid in situ SCC (BISC). Therefore, a causative connection has been 
suggested. However, only very little is known about the epidemiology of FdPV2. The 
aim of this study was to define its geno- and seroprevalence in healthy cats. 
For this purpose an FdPV2-specific PCR assay was used to analyse Cytobrush 
samples collected from 100 healthy cats. Moreover, an ELISA was established to test 
the sera obtained from the same cats for antibodies against the major capsid protein 
(L1) of FdPV2.  
The genoprevalence of FdPV2 amounted to 98%. Surprisingly, the quantities of viral 
DNA detected in the samples from the healthy cats exceeded the amounts detected 
in samples from feline BISC lesions. The seroprevalence was much lower, amounting 
to 22%. The concentrations of antibodies against FdPV2 were relatively low in 
healthy cats, whereas they were very high in cats with BISC. 
These observations suggest that FdPV2 is highly prevalent, even among healthy 
cats. However, cats that carry it on their skin mount only rarely an antibody response. 
In contrast, cats with BISC show a strong antibody response. Together, these data 
imply that active replication of FdPV2 may precede the occurrence of BISC, while it is 
no longer needed for the progression of the disease. 
 
Keywords: Cat, FdPV2, BISC, Papillomavirus, prevalence 
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Zusammenfassung 
 
Vetsuisse-Fakultät Universität Zürich (2015) 
 
Marco Dominic Geisseler 
 
Virologisches Institut, email@vetvir.uzh.ch 
 
Geno- und Seroprävalenz von Felis domesticus Papillomavirus Typ 2 (FdPV2) bei 
gesunden Katzen 
 
Papillomaviren können proliferative Hautläsionen auslösen, welche von benignen 
Hyperplasien bis zu Plattenepithelkarzinomen reichen. Asymptomatische Infektionen 
sind jedoch auch möglich. Mehrere Studien konnten FdPV2 DNA im Zusammenhang 
mit felinen Bowenoiden in situ Karzinomen (BISC) nachweisen. Eine kausative 
Verbindung wurde daher vermutet. Über die Epidemiologie von FdPV2 ist jedoch nur 
wenig bekannt. Das Ziel dieser Studie war es, die Geno- und Seroprävalenz bei 
gesunden Katzen zu bestimmen. 
Ein FdPV2-spezifischer PCR Assay wurde benutzt, um Cytobrush-Proben von 100 
gesunden Katzen zu analysieren. Weiter wurde ein ELISA etabliert, um Serumproben 
derselben Katzen auf Antikörper zu testen gegen das Major Capsid Protein (L1) von 
FdPV2. 
Die Genoprävalenz von FdPV2 lag bei 98%. Die Menge viraler DNA in Proben 
gesunder Katzen war dabei deutlich grösser als in Proben von felinen BISC-
Läsionen.  Die Seroprävalenz war viel tiefer und lag bei 22%. Die Konzentrationen an 
Antikörpern waren bei gesunden Katzen relativ tief während sie bei BISC-Katzen 
sehr hoch waren. 
Diese Beobachtungen deuten darauf hin, dass FdPV2 auch unter gesunden Katzen 
weit verbreitet ist. Katzen, welche das Virus auf der Haut tragen, zeigen jedoch nur 
geringe Antikörperreaktionen. Dem gegenüber zeigen Katzen mit BISC hohe 
Antikörpertiter. Dies kann bedeuten, dass eine aktive Replikation von FdPV2 vor der 
Entwicklung von BISC stattfindet, während sie für das Fortschreiten der Erkrankung 
nicht weiter vonnöten ist. 
 
Schlüsselwörter: Katze, FdPV2, BISC, Papillomavirus, Prävalenz 
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Introduction 
 
Papillomaviruses (PV) are small DNA viruses. They possess a double-stranded, 
circular genome of approximately 8 kilobasepairs (kbp). The genome typically 
contains a long control region (LCR) and up to ten designated translational open 
reading frames (ORF) that are all transcribed from the same strand. According to 
their location on the genome, these ORFs can be divided into early (E1-E8) and late 
(L1-L2) ORFs representing the early and late region, respectively. The early regions 
encode viral regulatory proteins whereas the late regions encode the capsid proteins. 
The capsid is of icosahedral shape and consists of major capsid protein L1, 
organised in 72 pentameric subunits, and minor capsid protein L2. The virion is non-
enveloped.1 
PV are classified based on similarities and identities of the nucleotide sequence of 
their L1 ORF. Currently, more than 190 types of PV are described and categorised 
into 29 genera.2,3 New PV types are continuously detected. PV can be found in 
various higher vertebrates including mammals, birds and reptiles.1,2 About two third 
of the described PV are human specific while the remaining types are specific for a 
wide variety of animals.2 Most host species are infected by multiple different PV 
species and types.4–7 
Clinically, PV show a specific cellular tropism for squamous epithelial cells.1 They can 
cause proliferative lesions ranging from benign warts to SCC.1,2 However, 
asymptomatic infection seems to be even more frequent.2 Up to 80% of people are 
infected asymptomatically with human PV.4 Apart from a few exceptions, PV tend to 
be highly species specific.1,8,9  Up to 2007, seven PV specific for Felidae were 
described. They were isolated from five different species, namely Felis catus, Puma 
concolor (Cougar), Lynx rufus (Bobcat), Panthera leo (Lion) and Panthera unica 
(Snow Leopard).10,11 All feline PV characterized that time were classified into the 
genus Lambdapapillomavirus.2 Interestingly, results from phylogenetic analysis 
proposed a coevolution of these viruses with their hosts.12 
Meanwhile, four different specific PV could be discovered in the domestic cat 
alone.2,3,13.The first sequences of the second feline PV were found in 2006.14 After 
sequencing its whole genome in 2007, it was named feline PV type 2 (FdPV2) and 
classified into the newly created genus dyo-Thetapapillomavirus.2,15 Although its 
7899bp genome is comparable to other PV in size, only 6 ORFs could be identified. 
The early region comprises of E6, E7, E1 and E2 whereas the late region comprises 
of L2 and L1.15 
Initially, FdPV2 DNA had been solely detected in feline Bowenoid in situ carcinomas 
(BISC). BISC is a rare premalignant state of squamous cell carcinoma (SCC).6,16 
Together with actinic keratosis, it belongs to the group of SCC in situ in felines.16,17 
Histologically, the neoplastic cells are limited to the epidermis leaving the basement 
membrane still intact.16 BISC are non-painful, pigmented, plaque like lesions within 
the haired skin. They can occur at any site of the body and are usually multiple. In 
some cases they were reported as partially alopecic and covered by crusts.6,16–18 The 
affected patients are typically older cats. No gender or breed predisposition could be 
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found. Surgical excision seems to be curative and no cases of metastasis have been 
reported so far. However, there are some reports of BISC that were left untreated 
and progressed to infiltrative SCC.16,17 
Only little is known about the epidemiology of FdPV2 infections. A pre-existing 
infection with feline immunodeficiency virus (FIV) does not seem to be associated 
with higher FdPV2 infection rates.19 Since its discovery, FdPV2 DNA has been found 
in BISC by various research groups with prevalences ranging from 18% to 100% (see 
table 6 in appendix). Besides, it was repeatedly amplified from viral plaques. Viral 
plaques are uncommon, non-neoplastic skin lesions that are clinically 
indistinguishable from BISC. Although complete regression has been reported, viral 
plaques are assumed to be precursor lesions of BISC.20,21 All these studies support a 
causative role of FdPV2 in the development of viral plaques and BISC. However, 
most of these studies only include small numbers of cats. Furthermore, FdPV2 could 
also be found in other types of feline skin lesions. As in BISC, the determined 
prevalence rates of FdPV2 in these other lesions show a rather wide variety, 
comparable to those found in BISC lesions.8,9,18,20,22–24 . Only few studies included 
samples from cat’s normal skin. Amplification of PV DNA using broad range primers 
always failed. However, in one study, a set of specific primers was used. FdPV2 DNA 
could be amplified from 52% of the samples.19 
There are no reports about the seroprevalence of FdPV2. Indeed, no assay for the 
measure of FdPV2 specific antibodies was developed so far. We therefore 
established a GST capture ELISA25 for detection of antibodies directed against the 
major capsid protein L1 of FdPV2. The principle of such an ELISA is the expression 
of the antigen as GST-fusion protein. The viral antigen in the form of this fusion 
protein could be bound to the ELISA plates coated with glutathione linked casein. 
The sera are tested to contain antibodies against the antigen, which is attached to 
the plates over the affinity of GST to glutathione. We already successfully used this 
technique to determine the seroprevalence of CPV1 and CPV3
26
 and EcPV2
27
 in 
corresponding populations. As a negative control in our study we used the major 
capsid protein L1 of CPV1. 
The aim of the present study was to shed light on the prevalence of FdPV2 in cats 
that do not suffer from any dermatological conditions. First, we determined the DNA 
prevalence in skin samples using specific primers and compared it to the prevalence 
found in BISC. According to the literature, FdPV2 was given a straight forward role of 
infecting feline skin cells and inducing BISC.28 If this was true, samples from normal 
skin should contain significantly less virus DNA. However, considering that other PV 
cause frequent subclinical infections, the working hypothesis of our study was that 
there should be no significant difference between healthy cats and cats with BISC in 
genoprevalence of FdPV2. Second, we wanted to determine the seroprevalence of 
FdPV2 and compare it with its genoprevalence. This would give us a first 
comprehension on how many cats that carried the virus on their skin reacted with 
seroconversion.  
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Materials and methods 
 
Sampling from cats 
For this study, we sampled 100 cats that had been presented to the Clinic of Small 
Animals, Vetsuisse-Faculty, Zurich, Switzerland. In order to screen “healthy” cats, we 
included only cats that suffered from issues without any known relationship to PV 
infection, i.e. any kind of skin lesions.  
The included cats showed a wide distribution in their age range. The youngest cat 
was only 3 months old whereas the oldest one was 17 years old. The age of 10 cats 
was unknown. The median age of the cats was 7 years. Twenty-two cats were less 
than one year old. From the 100 cats, 60 were male (44 neutered) and 40 were 
female (20 neutered). 76 cats were mixed breeds and 24 cats were purebred cats or 
descendants of two different purebred cats, respectively (Table 1). 
Six owners allowed us to sample multiple cats.  Five owners had two cats each that 
shared the same household. One owner even provided five cats that live on the 
same farm. As the cats were all presented for castration, they were healthy and 
young. The age varied from 0.4 to 1.1 years (median = 0.7). However, the age from 
the five cats that live on the farm was not exactly known. 
Skin cell samples were taken with a Cytobrush cell sampler (Deltalab; Barcelona, 
Spain). Two samples were taken from each cat. The first sample was taken from the 
haired skin around the mouth in the area where the left vibrissae are located. The 
second sample was taken from the right front paw, interdigitally between P3 and P4. 
If the described areas were not accessible for any reason (e.g. injury or bandage), 
the corresponding areas on the contralateral side were used for sampling. Briefly, a 
Cytobrush was wetted in 0.9% sterile NaCl solution and rubbed with rotating 
movement for 30 seconds on the skin of the described area. The handle of the 
Cytobrush was then cut off and the brush part placed in a sterile 1.5ml Eppendorf 
tube. 
Serum samples were taken during routine diagnostics not related to our study or 
when a new venous catheter was placed. To define a reliable seroprevalence, the 
ability to produce antibodies must be given. Therefore, animals with a known or 
suspected history of immunodeficiency or under treatment with immunosuppressive 
drugs were not included. If a current blood count of a candidate was available, it was 
checked and cats with hints for immunodeficiency were excluded. 
Two cats with lesions that had been histologically confirmed as BISC served as 
positive controls. The Cytobrush samples were taken directly from the BISC lesions. 
One cat was sampled at two lesions on the neck whereas the other cat was sampled 
at one lesion on the forehead resulting in a total of 3 samples. Serum samples were 
taken during routine diagnostics. 
As a negative control, Cytobrush and serum samples were taken from 5 specific 
pathogen-free (SPF) cats.29 The Cytobrush samples were taken from the same 
locations as described above. All serum and Cytobrush samples were stored at -
20°C until further analysis. 
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Breed Number of Cats 
Mixed breed 76 
Persian 4 
British Shorthair 3 
Bengal 2 
Burmese 2 
Maine Coon 2 
Siamese 2 
Siberian 2 
Birman 1 
Egyptian Mau 1 
Norwegian forest cat 1 
Norwegian forest cat x Persian 1 
Ocicat 1 
Ragdoll 1 
Turkish Van 1 
Table 1. Breed distribution in the sample cat population (n=100). 
 
PCR 
DNA was extracted from the Cytobrush samples using QIAamp® DNA Mini Kit 
(Qiagen; Basel, Switzerland) according to the manufacturer’s protocol with some 
modifications. The amounts of buffer ATL, proteinase K, buffer AL and ethanol were 
doubled to ensure that the complete Cytobrush was covered. The extracted DNA was 
finally dissolved in 100µl of buffer AE. 
Several published primer pairs were evaluated for their sensitivity to amplify PV DNA 
from feline skin samples.15,18,30–35 Additionally, new primers were designed to amplify 
parts of the FdPV2 E1, E6 and L1 ORF, respectively (table 2). The selected primer 
sets were ordered (Microsynth; Balgach, Switzerland) and tested for their 
sensitivities. PCR using REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-Aldrich; 
St. Louis MO, USA) was performed. As template DNA a dilution series of the plasmid 
containing the FdPV2 genome (see chapter “antigen production”) reaching from 109 
to 10-1 copies/μl was used. Amplification conditions were adopted from the literature. 
For the self-designed primers, the amplification conditions described above were 
used. The products were analysed by electrophoresis in a 1% agarose gel containing 
0.01% (w/v) ethidium bromide. The most sensitive set of primers was chosen for 
further analysis. 
Quantitative real-time PCR (qPCR) was performed using the iCycler iQ™ Real-Time 
PCR Detection System with the corresponding transparent 96-well plates (Bio-Rad; 
Hercules CA, USA). Reactions contained 10µl iQ™ SYBR® Green Supermix (Bio-
Rad; Hercules CA, USA), 0.6µl forward primer (10µM), 0.6µl reverse primer (10µM), 
3.8µl sterile water and 5µl template DNA. Negative controls contained no template 
DNA but additional 5µl of sterile water. Plates were sealed with iCycler iQ™Optical 
Tape (Bio-Rad; Hercules CA, USA) and centrifuged at 2000rpm for 10 minutes 
before performing qPCR. The following amplification conditions were used: 3 minutes 
at 95°C, 41 cycles of 10 seconds at 95°C and 30 seconds at 60°C and 1 cycle of 1 
minute at 95°C and 1 minute at 55°C. Afterwards temperature was raised by 0.5°C 
per cycle during 84 cycles of 10 seconds to create the melt curve. 
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As a reference gene, feline glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was chosen. A set of new primers was designed to amplify cat’s GAPDH. The 
nucleotide sequences of the resulting set of primers (fGAPDH_qPCR) can be found 
in table 2. qPCR was performed using the same protocol as described above.  
Calibration curves were created with dilution series of plasmids containing the 
desired DNA. For FdPV2, the plasmid containing the entire FdPV2 DNA (see chapter 
“antigen production”) was used. For GAPDH, PCR was performed to amplify the 
desired genome sequence using REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-
Aldrich; St. Louis MO, USA) and the primers catGAPDH_f (5’-TCA TCA TCT CTG 
CCC CTT CT-3’) and catGAPDH_r (5’-GTG AGC TTC CCA TTC AGC TC-3’). 
Amplification conditions were the same as described above (see chapter “Antigen 
production”). The obtained product was cloned using the TOPO TA Cloning® Kit with 
the pCR®2.1-TOPO® vector and chemically competent E.coli strain TOP10 cells 
(Invitrogen; Carlsbad CA, USA). The plasmids were extracted using the GenElute™ 
Plasmid Miniprep Kit (Sigma-Aldrich; St. Louis MO, USA) and verified by sequencing 
(Microsynth; Balgach, Switzerland). 
 
Antigen production for ELISA 
The FdPV2 L1 coding sequence (CDS) was amplified by PCR using Phusion™ High-
Fidelity DNA Polymerase (Finnzymes; Espoo, Finland). A pBluescript II KS(+) vector 
(Agilent Technologies; Santa Clara CA, USA) containing the whole genome of FdPV2 
served as template.15 Primers were specifically designed to amplify the FdPV2 L1 
CDS lacking the first ten (5’) codons. For the purpose of cloning, BamHI sites were 
added at the 5’ ends of the primers. The nucleotide sequences of the resulting set of 
primers (FdPV_L1_long) can be found in table 2. Amplification conditions were: 5 
minutes at 95°C, followed by 40 cycles of 1 minute at 95°C, 1 minute at 58°C, and 
1.5 minutes at 72°C with a final elongation step of 5 minutes at 72°C. The amplimer 
was cloned into the BamHI site of the pGEX-6P-1 vector (Pharmacia Biotech; 
Uppsala, Sweden) under the control of an isopropyl-β-D-thio-galactoside (IPTG) 
inducible T7 promoter. The resulting plasmid pGEX FdPV2 L1 was then propagated 
in E.coli strain DH10B. 
 
Primer set  Nucleotide sequence 
FdPV_L1_long Forward 5’-CGA CGG ATC CTT ATA TCT CCC ACC CTC CCC TG-3’ 
 Reverse 5’-AAT AGG ATC CTC ATT TGC GGG TGC GTT-3’ 
FdPV2_E1 Forward 5’-CAG CTC CCA GTC TCC TAA CG-3’ 
 Reverse 5’-GCT GTG CCA TTA TCT GAG CA-3’ 
FdPV2_E6 Forward 5’-GCG TAT TTT GCG GAA CAC TT-3’ 
 Reverse 5’-CCA GAT CCC TGT GCA AAA AT-3’ 
FdPV2_L1 Forward 5’-CCC GAA ACA GAC GCA ATT AT-3’ 
 Reverse 5’-TAT TGC CAA ACC CAG TGT CA-3’ 
fGAPDH_qPCR Forward 5’-GTG GAG GGA CTC ATG ACC AC-3’ 
 Reverse 5’-GTG AGC TTC CCA TTC AGC TC-3 
Table 2. Nucleotide sequences of novel primer sets used in this study. BamHI site within the 
FdPV_L1_long are underlined. 
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To control the correct insertion of the FdPV2 L1 sequence, the extracted plasmids 
were analysed by restriction enzyme digests and the integrity of the sequence was 
confirmed by sequencing (Microsynth; Balgach, Switzerland). The isolated plasmid 
DNA was transformed into E.coli strain BL21(DE3), which express the T7 polymerase 
upon IPTG induction. Protein expression was performed as described previously with 
minor modifications.36 The bacterial cells were grown in 15ml LB medium containing 
100μg/ml Ampicillin at 25°C with shaking (220rpm) until an OD600 of 0.3. Protein 
expression was induced by adding 0.25mM IPTG and the cells were incubated over 
night at 25°C with shaking (220rpm). After centrifugation the pelleted bacteria were 
solved in 1.5ml buffer L (40mM Tris pH 8.0, 200mM NaCl, 1mM EDTA and 2mM 
DTT) supplemented with Complete Protease Inhibitor Cocktail (Roche; Mannheim, 
Germany) and lysed by sonication. ATP (2mM) and MgCl (5mM) were added and the 
lysate was incubated for 1 hour at room temperature. Urea was slowly added over 5 
minutes to a final concentration of 3.5M. After another incubation of 2 hours at room 
temperature, the mixture was split into 2 equal parts and dialysed against buffer L 
using 7K MWCO Slide-A-Lyzer® Dialysis Cassettes (Thermo Scientific; Rockford IL, 
USA) over night at 4°C. Buffer was exchanged and dialysis was carried on for 2 
hours. After centrifugation the obtained antigen mix was diluted 1:1 with glycerol 
100% and stored at -20°C. 
The protein expression procedure was simultaneously performed with three different 
E.coli strain BL21(DE3) cultures containing different pGEX-6P-1 vector derivatives. 
The first contained the FdPV2 L1 CDS fused to the GST CDS whereas the second 
contained a CPV1 L1 CDS fused to the GST CDS.26 The third culture contained the 
GST CDS only. All ELISA assays reported in this study were performed with antigen 
from the same lot of antigen production. 
 
GST capture ELISA 
Polysorb 96-well plastic plates (Nunc; Roskilde, Denmark) were coated at 4°C over 
night with 50mM sodium carbonate buffer pH 9.6 containing 0.2% glutathione casein 
(kindly provided by Martin Müller DKFZ, Heidelberg, Germany). The plates were then 
washed three times with PBS buffer containing 0.3% Tween 20 (PBS-T) and blocked 
at 37°C for 1h with casein buffer (PBS-T containing 0.2% casein). After washing 
three times with PBS-T, the plates were incubated at 37°C for 1h with the GST 
tagged antigen diluted 1:10 in casein buffer.  The plates were washed again three 
times with PBS-T. 
The sera had been diluted 1:500 in casein buffer, mixed with an equivalent of lysed 
untransformed E.coli strain BL21 (DE3) and incubated at 4°C for 30min to block 
reactions with contaminating bacterial proteins.25,26,36 The plates were then incubated 
with the prepared sera at 37°C for 1h and washed again three times with PBS-T. 
Goat Anti-Feline IgG conjugated to Horseradish Peroxidase (HRP) (Southern 
Biotech; Birmingham AL, USA) diluted 1:1000 in casein buffer was added as 
secondary antibody and the plates were incubated again at 37°C for 1h. After 
washing six times with PBS-T, substrate (78mM CH3COOH, 24mM CH3COONa, 
50mM NaH2PO4, 2mM ABTS [Roche; Rotkreuz, Switzerland] with 1.25mM H2O2 
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applied shortly before use) was added.  Absorbance was measured after 45min at 
405nm in a Sunrise™ microplate reader (Tecan; Männedorf, Switzerland). 
The cat sera were tested in triplicates against the antigen FdPV2 L1-GST and, as a 
negative control, against CPV1 L1-GST. For a subset of samples the ELISA was 
repeated. The according samples were then tested in duplicates against CPV1 L1 
and against GST alone. In order to normalize the results of the different plates, the 
same positive and negative control sera were used on every plate. No serum was 
added in six wells serving as a plate control. 
 
Data analysis and presentation 
The Cq-values obtained from qPCR were converted into absolute numbers of copies 
of FdPV2 and GAPDH in each sample using the equation of the corresponding 
calibration curve. In order to obtain comparable results, in each sample the absolute 
number of FdPV2 copies was divided by the corresponding absolute number of 
GAPDH copies. 
Serum samples were tested in triplicates in ELISA. To prevent outlier results from 
influencing the data, the median of the three observed values was used for further 
analysis. Plate to plate variability was compensated by dividing every value by the 
mean of the control sera values from the corresponding plate and multiplying the 
result by the mean of all control sera from all plates. 
Different methods of setting a cut-off value (COV) were evaluated for the qPCR and 
ELISA. In method 1 (named SNC), the COV was set equal to the strongest reaction 
of a negative control serum. In method 2 (named WPC), the weakest reaction of a 
positive control serum was used as reference. In method 3 (named MSWC), the 
mean of the values used in methods 1 and 2 was taken.26 In method 4 (named 
XBP2S), the X-Bar-plus-2s procedure was applied.25,37,38 The mean of all negative 
control samples was calculated and 2 standard deviations were added. 
Data was organised using Microsoft Excel 2010 (Microsoft; Redmond WA, USA) and 
further statistical analysis was done by IBM® SPSS® Statistics version 20 software 
(IBM; Armonk NY, USA). Figures were generated using R (Free Software 
Foundation; Boston, USA). Boxplots are produced using R with default settings. The 
solid bar represents the median, the box range from the first to the third quartiles, and 
the whiskers extend to the lowest and highest datum still within 1.5 times the 
interquartile range. Data not included within the whiskers are individually presented. 
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Results 
 
PCR 
In order to test the skin samples for the presence of FdPV2 specific DNA, a qPCR 
was developed and applied. First, different FdPV2 specific primer sets were 
compared and the most sensitive was chosen. Second, the amount of FdPV2 DNA 
was determined using qPCR with GAPDH as reference gene. Third, a COV was set. 
Fourth, the DNA-prevalence of the sample population was determined. 
 
Evaluation of PCR primer pairs for the detection of FdPV2 specific DNA 
The sensitivities of different primer sets were tested with a dilution series of a plasmid 
containing the FdPV2 DNA. We tested ten of the published primer sets that had been 
used to screen samples for FdPV2. Using the same amplification conditions as 
described in the according publications, six of these ten primer sets were not able to 
detect the plasmid even in a concentration of 109 copies/μl (Table 3). 
 
Primer set Minimal amount (copies/μl) 
E5
+
/E5
-
 
30
 >10
9
 
IFNR-2/IDNT-2 
6,30,38
 >10
9 
jmpSA-F/jmpSA-R 
31
 >10
9
 
MY09/MY11 
3,7,21,24,25,31,32,38,39
 >10
9
 
NO1/NO2 
30
 >10
9
 
PV3/PV5 
33
 >10
9
 
FAP59/FAP64 
3,5–7,18–21,23,34,38,39
 10
8 
CP4/CP5 
14,35
 10
6 
FdPV2_L1 10
6 
A16/A37 
15
 10
4 
FdPV2_E6 10
2 
JMPF/JMPR
3,7,18–21,23–25
 10
2 
FdPV2_E1 10
0 
Table 3. Minimal amount of FdPV2 plasmid DNA (copies/μl) needed for a positive PCR 
result. >10
9
 = no positive result within the range of the used DNA dilution series (10
9
-10
-1
 
copies/μl). 
 
For the other four primer sets, the minimal amount of DNA in the sample needed for 
detection varied from 102 - 108 copies/μl. All of the three newly designed primer sets 
succeeded to detect the template DNA. The minimal amount needed varied from 1 - 
106 copies/μl. The primer set designed to amplify the FdPV2 E1 ORF turned out to be 
the most sensitive of all tested sets. FdPV2 plasmid DNA in a minimal amount of one 
copy/μl was enough to repeatedly obtain positive PCR results. We decided therefore 
to use this primer set for our qPCR. The results of the conventional PCR are listed in 
table 6 (see appendix). 
 
Calibration curves for calculation of copy numbers of FdPV2- and GAPDH-DNA 
Serial dilutions of cloned FdPV2 and GAPDH DNA templates were used to evaluate 
the equations to convert the Cq values into copy numbers of DNA molecules. The 
equations of the calibration curves were for GAPDH Cq = -3.98x log(molecules) + 
39.34 (R2 = 0.9767) and for FdPV2 Cq = -3.99x log(molecules) + 40.16 (R
2 = 0.9951) 
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(Figure 1). This resulted in efficiencies of 78.3% for the GAPDH-qPCR and 78.1% for 
the FdPV2-qPCR. 
 
 
Figure 1. Calibration curves for qPCR. Dilution series of cloned feline GAPDH cDNA and 
FdPV2 DNA were used as template and qPCR was performed using specific primer sets (see 
above). The resulting equations of the calibration curves were for GAPDH Cq = -3.98x 
log(molecules) + 39.34 (R
2
 = 0.9767) and for FdPV2 Cq = -3.99x log(molecules) + 40.16 (R
2
 = 0.9951). 
These equations were used to quantify the results of the qPCR using the same primer sets but 
the DNA extracted from the Cytobrush samples as templates. 
 
Measurement of the FdPV2 DNA copies of the Cytobrush samples 
The readily established qPCR assay for FdPV2 was used to evaluate the viral DNA in 
the Cytobrush samples collected from the healthy sample population. The results 
were quantified using calibration curves and converted to comparable values using 
feline GAPDH as a reference gene. The log-transformed ratios are shown as box 
plots in figure 2A. The medians of the negative controls were significantly lower than 
these from the positive controls. The medians of the samples were for both, the 
samples from the head as well as the samples form the paw between the positive 
and the negative controls. To further explore the distribution of the ratios, the log-
transformed ratios were plotted as histogram and shown in figure 2B. The distribution 
of the transformed ratios of the samples collected from the heads as well as these 
collected from the paws resembled a normal distribution with additional data points at 
the lower end. To better visualize the distribution of the data, the normal distribution 
with the mean and the standard deviation of the positive and negative controls were 
included. The sum of the two normal distribution curves approximated the curve of 
the density function from the sample population. 
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Figure 2. (A) Boxplot of the log-transformed ratios of FdPV2 to GAPDH molecule numbers. The 
positive controls (C
pos
paw, C
pos
head) and the negative controls (C
neg
paw, C
neg
head) are shown as 
white boxes and the samples (Spaw, Shead) as grey boxes. The boxes and whiskers are used as 
defined in the method section. (B) Histogram of log-transformed ratios of FdPV2 to GAPDH 
molecule copy numbers. A density plot is overlaid as solid black line and the normal distribution 
with mean and standard deviation of the negative and positive control samples are shown as 
dashed lines. The sum of both normal distributions is shown as a solid grey line. 
 
Assessment of a meaningful cut-off value (COV) for the qPCR 
In order to group the samples into positive and negative results, a COV had to be set.  
Different methods of setting a COV were compared (Table 4). The highest 
prevalence resulted if either the SNC method (COV = 0.188) or the XBP2S method 
(COV = 0.315) was applied. With either method 169 out of 189 samples would have 
been classified as positive, which corresponded to a prevalence of 89%. Using the 
MSWC method (COV = 1.970), 129 samples could be counted as positive 
(prevalence = 68%). The lowest value for the prevalence resulted from an application 
of the WPC method (COV = 3.754). Only 111 samples were positive in that case, 
which corresponded to a prevalence of 59%. For further analysis of the data, we 
used the COV described in XBP2S as this is a widely accepted method for setting a 
COV.37 
 
COV p+ p- h+ h- p+/h+ p-/h- p+/h- p-/h+ 
SNC 93 7 87 13 82 2 11 5 
WPC 67 33 52 48 40 21 27 12 
MSWC 74 26 64 36 51 13 23 13 
XBP2S 90 10 83 17 77 4 13 6 
Table 4. Number of positive and negative cats when applying different COV. (criterions and 
combinations of are as followed. p+: paw sample positive; h+: head sample positive; p-: paw 
sample negative; h-: head sample negative) 
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Determination of the genoprevalence of FdPV2 in the sample population 
The determined COV was used on the ratios of the sample population. Out of the 
200 DNA samples, 189 could be used for the study. In nine samples, the qPCR with 
FdPV2 E1 specific primers amplified an unspecific by-product as recognized by 
analysis of the melting curves. The resulting quantification cycle (Cq) value was false 
high. Eight of these nine false high values were above the COV after quantification 
and therefore taken out of further analysis. One value was below the COV and 
treated as a normal negative result. In three other samples amplification of GAPDH 
failed. Calculating the copy number of FdPV2 per GAPDH was consequently not 
possible and the samples were taken out of further analysis. The determined Cq 
values varied from 14.7 to 37.4. Negative samples were labelled “n/a”. In order to 
calculate a comparable value, Cq was set as 40. 
Among the 189 samples used for further analysis, the calculated FdPV2 DNA copies 
per GAPDH varied from 4.0·10-4 to 9.3·104 in the samples from the head and from 
5.9·10-3 to 2.0·105 in the samples from the paw. Among the negative control samples 
FdPV2 DNA copies per GAPDH varied from 1.2·10-2 to 8.8·10-2 in the samples from 
the head and from 2.0·10-4 to 1.8·10-2 in the samples from the paw. In nine of these 
ten samples no specific FdPV2 DNA could be amplified in qPCR. Cq was therefore 
set as 40 as described above. However, in one paw sample specific FdPV2 DNA 
could be amplified. Cq was 35.9. The calculated number of FdPV2 DNA copies per 
GAPDH was 1.6·10-1. 
No relationship between the copy numbers in head and paw samples could be found. 
A high number of copies in the head sample was not necessarily accompanied by a 
high number of copies in the corresponding paw sample. The positive control 
samples, which had been taken directly from BISC lesions, varied from only 3.7·100 
to 1.7·102. 
A COV was set at 0.367 according to method XBP2S as described above. 169 
samples were above the COV whereas 20 samples remained below. From these 20 
samples, 13 were taken from the head and seven from the paw. Ninety-eight cats 
had at least one positive sample and were therefore counted as FdPV2 DNA positive. 
The two FdPV2 DNA negative cats both had two samples of sufficient quality (see 
exclusion criteria above) and did not have any relation to each other. Summarized, 
the DNA prevalence of FdPV2 in the studied population was determined to be 98%. 
Further statistical analysis was not performed as the group of negative samples is too 
small to expect meaningful results. 
 
GST capture ELISA 
In order to test the serum samples for the presence of FdPV2 specific antibodies, an 
ELISA was developed and applied. First, the antigen coating of the plates and the 
measurement of antibodies in the control sera were tested (see tables 5 and 6 in 
appendix). Second, the antibody titres of all samples were determined and 
normalized (see table 8 in appendix). Third, a meaningful COV was set. Fourth, the 
seroprevalence of the sample population was determined. 
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Assessment of the COV for the ELISA 
We evaluated the four methods used already for the qPCR to calculate the COV for 
the ELISA readouts. 
The corresponding seroprevalences for FdPV2 varied considerably. Setting the COV 
equal to the strongest reaction of any negative control (SNC, COV = 0.292) resulted 
in 27 positive samples. If set equal to the weakest reaction of any positive control 
(WPC, COV = 1.743), no sample serum could be considered as positive. Taking the 
mean of these two values (MSWC, COV = 1.017) gave only one positive sample. The 
COV of the X-Bar-plus-2s method (XBP2S, COV = 0.315) was close to the one 
obtained by the SNC method. If applied, 24 samples were positive. For further 
analysis, the COV was set relying on the XBP2S method as we used this method in 
the qPCR already. 
 
COV F+ F- F+/C+ F-/C- F+/C- F-/C+ 
SNC 27 73 2 73 25 0 
WPC 0 100 0 98 0 2 
MSWC 1 99 1 98 0 1 
XBP2S 24 76 2 76 22 0 
Table 5. Number of positive and negative serum samples when applying different 
COV. (F+/-: FdPV2 ELISA positive/negative; C+/C-: CPV1 ELISA positive/negative) 
 
The reaction of the sera against CPV1 antigen was tested as a negative control in a 
separate ELISA. A GST-CPV1 L1 fusion protein instead of a GST-FdPV2 L1 was 
used to coat these assay plates. All other reagents and dilutions were applied as in 
the FdPV2 specific assay. Similar to the FdPV2 ELISA, an individual COV was 
assessed with the XBP2S method and set to 0.472 for the CPV1 ELISA. 
 
Analysis of antibody titres in cat serum by ELISA 
The serum samples were screened for antibodies against FdPV2 and, as a negative 
control, against CPV1 using a GST capture ELISA. Absorbance was measured after 
45min at 405nm. The sample sera reacted against FdPV2 with an OD ranging from 
0.154 to 1.094 (mean = 0.301) and against CPV1 with an OD ranging from 0.162 to 
1.096 (mean = 0.242). Setting the COV using the XBP2S method resulted in a COV 
of 0.315 for FdPV2 as described above and 0.472 for CPV1. The reactions against 
FdPV2 of 24 serum samples were above the COV and could thus be considered 
positive while 76 serum samples were counted as negative. Two serum samples 
showed a reaction against CPV1 above the according COV (Figure 3). 
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Figure 3. Histogram plot of the corrected ELISA OD values from the cat’s serum samples 
(without control sera) for the FdPV2 specific antibodies (upper panel) and CPV1 specific 
antibodies (lower panel), respectively. Ranges of the bins are 0.02 OD. Individual values are 
indicated as rug plot below the bars and the density of the distribution is shown as solid line. 
Setting the COV for the FdPV2 specific ELISA as described in the XBP2S method (COV = 
0.315) resulted in 24 positive samples. Using the MSWC method (COV = 1.017) resulted in only 
one positive sample (see arrows). Setting the COV for the CPV1 specific ELISA as described in 
the XBP2S method (COV = 0.472) resulted in 2 positive samples. 
 
To incorporate the CPV1 control in the data analysis, the corrected OD values of the 
FdPV2 specific ELISA were plotted against the corrected OD values of the CPV1 
specific ELISA (Figure 4). As mentioned above, two of the 24 positive serum samples 
showed a reaction against CPV1 with an OD above the according COV (circles on 
the right side of the vertical and above or close to the diagonal line on figure 4). The 
ELISA was repeated with these samples. CPV1 L1 (tagged to GST) and GST alone 
were used as antigens. In both samples the reactions against GST alone were as 
strong as the reactions against CPV1 L1-GST. The samples were therefore 
categorised as negative for antibodies against CPV1 as well as against FdPV2. The 
seroprevalence of FdPV2 was corrected down to 22%. 
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Figure 4. OD values of the FdPV2 specific ELISA versus OD values of the CPV1 specific 
ELISA. The respective COVs of the assays as determined by the XBP2S method is shown as 
vertical line for the FdPV2 ELISA and as horizontal line for the CPV1 ELISA. To visualize data 
points with values of the CPV1 OD above the FdPV2 OD, a diagonal line is drawn. Samples are 
shown as circles and negative controls as black dots. The positive control is out of the range of 
the axis. 
 
The OD of the negative control sera ranged from 0.184 to 0.291 (mean = 0.225) and 
the one of the positive control sera from 1.743 to 2.041 (mean = 1.892) in the FdPV2 
specific ELISA (see tables 7 and 8 in appendix). Bonferroni statistical test was used 
to compare the mean OD of the sample sera with those of the positive and negative 
control sera, respectively. The mean OD of the positive control sera was significantly 
higher than the mean OD of the sample sera (p=0.000), whereas the mean OD of the 
negative control sera did not differ significantly from the mean OD of the sample sera 
(p=0.986). Fisher’s Exact Test was used to compare subgroups of the sample 
population (see figure 6 in appendix). No difference in seropositivity could be found 
between purebred and mixed breed cats (p=0.386). The sera of male cats were as 
often tested positive as the sera of female cats (p=0.448). There was no difference 
between intact individuals and castrated ones (p=0.061). The seropositive cats had a 
median age of 12.0 years. This is significantly older (Univariate Analysis of Variance, 
p=0.000) than the negative cats that had a mean age of 4.3 years. Yet, the age of 
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three positive and seven negative cats was not known. The 15 cats living in multiple 
cat households were all tested negative. 
 
 
Correlation of ELISA and PCR 
Results obtained from ELISA and PCR were compared. The log-transformed ratios 
from the Cytobrush samples isolated from head were plotted against the ones from 
the paw and the size of the dot corresponded to the OD value of the FdPV2 specific 
ELISA (Figure 5). 
 
 
Figure 5. Scatter plot of log-transformed qPCR copy numbers ratios of FdPV2 DNA to GAPDH 
DNA in head and paw samples and the according ELISA OD value from the serum sample. 
White circles represent FdPV2 ELISA negative cats from sample population, grey dots 
represent FdPV2 ELISA positive cats, and black dots represent positive and negative control 
cats. The drawing sizes of the circles/dots indicate the ELISA OD value. The vertical and 
horizontal lines are set at the level of the COV (0.202). The numbers of FdPV2 ELISA positive 
and negative cats in each of the four categories describing the genoprevalence of FdPV2 on 
head and paw are specified. 
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Data points corresponding to cats with similar ratios of FdPV2 DNA to GAPDH DNA 
on paw and head would lie close to a diagonal line through the origin with a slope of 
1. This prospective correlation was not obvious. However there was a tendency of 
the larger circles (corresponding to FdPV2 ELISA positive cats) within the region of 
qPCR positive in paw- and head-samples and small circles within the region of 
negative qPCR samples. Though, some cats had different ratios of FdPV2 and 
GAPDH DNA in the paw- and head-samples. 
 
Cats tested positive in ELISA showed a large variation in PCR results. The lowest 
observed copy number of FdPV2 per GAPDH was only 4.0·10-4 whereas the highest 
value was 1.4·103. Two seropositive cats had less than one copy of FdPV2 per 
GAPDH in both samples and two other had one negative PCR sample each. None of 
the positive control samples had more than 200 copies of FdPV2 per GAPDH. The 
lowest FdPV2 DNA content in a sample from the seronegative cats was 9.0·10-4, 
while the highest was 2.0·105. One seronegative cat had more than 9.0·103 copies of 
FdPV2 per GAPDH in both samples. The two cats that remained DNA negative were 
tested negative in ELISA as well. Overall the seronegative cats had on average 
almost 15 times as many copies of FdPV2 DNA (mean 1.4·103) than seropositive 
cats (mean 1.0·102). 
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Discussion 
 
In this study, we determined the prevalence of FdPV2 in a population of 
dermatologically unremarkable cats by two methods, (1) detection of viral DNA, (2) 
detection of specific serum antibodies. We could amplify specific FdPV2 DNA from 
98% of the skin samples. This DNA prevalence was thus much higher than the one 
previously reported of 52%.19 It was comparable to the FdPV2 DNA prevalence found 
in BISC and viral plaques. With this data we could confirm our hypothesis that there 
would be no significant difference in DNA prevalence in samples from BISC lesions 
or from normal skin. 
Various other studies reported the screening of feline skin samples for PV by 
immunohistochemistry (IHC). In those studies, IHC was used to detect the major 
capsid protein, which is the product of the L1 ORF. This ORF is only expressed in 
productively PV infected cells late in the viral replication cycle.1,21 Unproductively 
infected cells or cells with virus in the very early stage of the replication cycle cannot 
be detected by immunohistology. 
As PCR detects genome sequences regardless of gene expression, it is suggested to 
be the more sensitive method for PV detection than IHC.6 Furthermore, PCR is 
easier to apply than IHC. Consequently, in most of the other studies PCR was used 
for PV detection. An overview of the studies that used PCR for PV detection in skin 
samples of cats is given in table 6 (see appendix). In some of the studies, specific 
DNA of FdPV2 could be detected using broad range or specific primers. The reported 
FdPV2 DNA prevalence rates of these studies, however, are often much lower than 
the DNA prevalence found in our study. In the majority of the existing studies, DNA 
was extracted from formalin-fixed biopsy samples. Formalin-fixation is known to 
cross-link and fragment genomic as well as viral DNA.39 A low yield of intact DNA 
might result, which lowers the sensitivity of PCR either by decreased primer affinity or 
by strand-breaks within the targeted sequence. Likewise, Munday et al. showed that 
amplification of PV DNA from cotton-tipped swabs was a more sensitive method than 
amplification from formalin-fixed tissue.7 In our study, we used Cytobrushes to take 
skin cell samples. Cytobrushes are normally used to take cell samples from 
mucosae. Chalvardjian et al. compared the uptake of cells of cotton-tipped swabs 
and Cytobrushes by performing endocervical sampling in women. The samples taken 
with a Cytobrush contained on average at least 17 times more endocervical cells 
than the samples taken with a cotton-tipped swab in 87% of the cases.
40
 In our study, 
we took the Cytobrush samples from the haired skin. Only 3 out of 200 Cytobrush 
samples were negative in qPCR for GAPDH and, therefore, 197 samples were 
apparently of sufficient quality. This demonstrates that Cytobrushes are a very useful 
and efficient tool for collecting cell samples even from the haired skin. 
Comparing different types of feline skin lesions, the DNA prevalence of FdPV2 
seemed to vary considerably.  Low rates of FdPV2 were found especially in ISCC 
and non-SCC lesions. However, it is difficult to compare all the published studies 
among each other and with our own study, since many different primer sets were 
used for PCR. It was shown that consensus primers are not sensitive enough to 
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detect small amounts of specific FdPV2 DNA.19 In order to choose the most sensitive 
primer set, we evaluated 10 of the published and 3 novel primer sets. Every primer 
set was tested with the same template DNA, a dilution series of a plasmid containing 
the entire FdPV2 genome and the recommended cycling protocol in a conventional 
PCR. The results revealed a remarkable difference in the sensitivity among them. In 
our evaluation, six primer sets that had been used in other studies, failed to detect 
FdPV2 DNA even at a predetermined concentration of 109 copies/μl. This might be 
partially explained by the fact that we used different cycling devices and polymerase 
suppliers. However, low sensitivity of the used primer sets may still be a major 
reason why other studies detected only low rates of FdPV2 in certain types of 
lesions. A causative role of FdPV2 should not be suggested only by a higher 
detection rate in certain types of lesions if different PCR with different primer sets and 
amplification protocols were used. One study found FdPV2 DNA in 34 of 88 (39%) 
skin samples from normal skin.19 However, we could detect FdPV2 DNA in 169 of 
189 (89%) skin samples. The much higher rate could be explained again with the 
sensitivity of the primers as the primer set used in our study turned out to be 100 
times more sensitive, detecting FdPV2 DNA even at a template concentration as low 
as one copy per microliter. 
The primers used in this study were designed to amplify the genome sequence of the 
FdPV2 E1 ORF. As in other PV, the 1805bp FdPV2 E1 ORF is the largest ORF in the 
genome.1,15 Regarding the PV life cycle, the E1 ORF product is required for initiation 
and elongation of DNA synthesis. Together with the L1 and the L2 ORF, it is more 
conserved than the other ORFs.1 One study even identified two 21bp regions in the 
E1 ORF as being the most highly conserved regions among all PV species 
examined.33 Of note, the specificity of this primer set could still be confirmed by 
sequencing the amplified products. 
GAPDH was chosen as reference gene as it is generally accepted and 
recommended in the literature.
41
 Calculating the number of FdPV2 copies per 
GAPDH allows comparing samples with different amounts of cells and total DNA. 
Nevertheless, remarkable differences could be found from cat to cat as well as in the 
corresponding samples from the head and the paw of the same cats. In some 
samples more than 105 viral DNA copies could be detected per GAPDH copy. In 
other samples there was hardly more than one viral DNA copy per 2.5·103 GAPDH 
copies. The minimal DNA amount needed for the different primer sets to amplify 
FdPV2 DNA varied considerably from only one DNA copy/μl to more than 109 DNA 
copies/μl. Keeping this difference in sensitivity in mind, the variability of viral DNA 
load found in our study agrees with another study where infection with FdPV2 was 
suggested to be limited to focal areas on the skin.19 Since FdPV2 DNA was detected 
in normal feline skin before, quantification of the amount of viral DNA was 
consequently proposed to rule out a possible causative role of FdPV2 in certain types 
of lesions.19 In our study we used Cytobrush samples taken directly from BISC 
lesions as positive controls. However, the amount of FdPV2 DNA in these samples 
was rather low compared to the samples taken from the normal skin. None of these 
control samples had more than 200 FdPV2 copies per molecule of GAPDH DNA. 
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PV infection is often equated to malignant tumour formation. However, asymptomatic 
infection is more common. Up to 80% of humans are infected asymptomatically with 
human PV.18 Various animal species have also been investigated regarding PV 
infections and asymptomatic PV infections were found regularly. The prevalence 
varies from species to species. Interestingly, primates showed prevalence rates 
similar to that of humans.5 However, no PV DNA could be amplified from samples of 
the normal skin of cats for a long time. Asymptomatic infection was therefore 
declined. The ‘hit and run’ carcinogenesis model was used to explain transformation 
of normal skin cells into neoplastic cells by transient PV infection.6  However, a 
recent study found FdPV2 DNA in skin samples of 39% of healthy cats.19 In our 
study, we could detect FdPV2 DNA in at least one Cytobrush sample of 98% of the 
cats investigated. Cytobrushes absorb cells from the surface of the skin. 
Subsequently, the cells are lysed in order to extract the DNA for PCR. Therefore, it is 
not clear if the extracted PV DNA originates from infected epithelium cells or from 
virions that were attached to the skin’s surface.  To determine the rate of 
asymptomatically infected animals only from PCR results might therefore be 
incorrect. However, it can be stated that 98% of the cats had certainly been in close 
contact with FdPV2. Considering the high tenacity of PV particles, it makes sense 
that high amounts of virus are shed to build up an infectious virus reservoir on 
biological surfaces. 
The samples used as negative controls were taken from SPF cats and exact 
instructions had been given on how to take the samples to ensure sufficient quality 
for analysis. These cats originated from special SPF catteries and were kept as 
laboratory animals in facilities with high hygiene standards. Only specifically trained 
personnel were allowed to enter the SPF facilities and to have contact with the cats. 
The health status of the cats was checked at regular intervals in order to attest 
absence of certain pathogens.29 Originally, they had not specifically been tested for 
FdPV2. Thus, the fact that FdPV2 is such highly prevalent among normal cats but 
could not be detected in the samples from those SPF cats, validates the high quality 
of the SPF facility. Such SPF facilities seem to represent a valuable source for 
collecting different negative control samples also for other purposes. Using a 
reference gene in PCR such as GAPDH was important to confirm a sufficient quality 
of the Cytobrush sample and DNA extraction. Specific FdPV2 DNA could be 
amplified in qPCR from one sample taken from the paw. However, after quantification 
the number of FdPV2 copies per GAPDH was within the range of the negative 
samples.  
In our study, we determined the seroprevalence of FdPV2 to be 22% in the 
investigated population of cats. This was much lower than the DNA prevalence. As 
expected, the determined seroprevalence is dependent on the applied COV, which 
were calculated from the OD values of the control sera. The positive control sera 
were collected from BISC positive cats and the negative control sera from SPF cats. 
The positive control sera had very high OD values compared to the most sera tested 
in the analysis. Therefore, the inclusion of these values into the determination of the 
COV (WPC and MSWC) lead to high COV and consequently to very low 
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seroprevalence. In contrast, when applying methods to calculate the COV, which are 
based only on the negative control sera (SNC and XBP2S), the seroprevalences 
seem to be more reasonable. It is known that PV do not necessarily induce robust 
antibody responses.2 Furthermore, the age distribution of the sample population 
might be an explanation for the low seroprevalence. In our study, 22 out of the 100 
tested cats were less than 1 year old. All of them were tested negative in the ELISA. 
A study in humans showed that it can take many months from the onset of an 
infection with cutaneous HPV types to seroconversion.42 It could therefore be that 
many cats just did not have enough time to produce detectable amounts of 
antibodies. On the other hand, we do not know how long after seroconversion 
specific antibodies remain in detectable amounts in the sera. Animals that are now 
seronegative could have seroconverted before while antibody levels dropped over 
time. In humans, however, levels of antibodies against HPV were found to be stable 
even after more than 10 years.42. 
In our study the seropositive cats were significantly older than the seronegative cats. 
This may fit with the fact that BISC is more common in old cats.16,17 Nevertheless, the 
BISC affected cats that served as positive controls showed significantly higher 
amounts of antibodies than any cat from the sample population. In other species, it 
was shown that the neutralizing antibodies cannot induce the regression of the PV 
infection once it is established.43 The same seems to be true in cats. 
The L1 major capsid protein of PV is considered to induce neutralizing antibodies 
that are mainly type specific.43 However, two serum samples showed reactions 
against CPV1 that were as strong as or even stronger than against FdPV2. An ELISA 
was performed to evaluate the reaction of these samples against CPV1 L1-GST and 
GST alone as antigens. All of the tested sera reacted against GST alone as strong as 
against CPV1 L1-GST. GST is an enzyme that plays a key role in cellular 
detoxification. It is not only present in mammals but also in fungi, helminths and 
bacteria.
44,45
 Therefore it can be assumed that the mentioned five serum samples 
contained antibodies against GST. Both ELISA antigens, FdPV2 L1 and CPV1 L1, 
were tagged to GST because GST allows non-denaturing adhesion to coated 
glutathione-conjugated casein and, thus, formation of virus-like particles as antigen. 
Alternatively, these two sera might contain antibodies against bacterial proteins that 
had not been washed away completely after incubating the plates with the antigen. 
However, we did not expect such reactions since the sera had been pre-incubated 
with bacterial lysate. In both cases the results would be false positive. Consequently, 
these sera were not considered positive, neither for FdPV2 nor for CPV1. This shows 
the importance of a negative control when using a GST capture ELISA. 
Comparing the individual cat’s results from the ELISA and the qPCR, a certain 
correlation might be expected. In humans, individuals with a high HPV DNA load are 
more prone to be also seropositive.42 Likewise, intimate contact with FdPV2 might as 
well induce the production of antibodies against it. Therefore, cats with a high virus 
load are suggested to be more often seropositive. In our study, no such correlation 
could be found. On the contrary, significantly higher amounts of FdPV2 DNA were 
detected in seronegative cats. The highest number of copies per GAPDH was 140 
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times higher than the highest number found in the samples of the seropositive cats. 
Individuals sharing the same household did not seem to influence each other with 
regard to either the serological or the PCR outcome. One cat showed a negative paw 
sample (3.1·10-2) whereas its partner animal had the highest amount of virus DNA on 
its paw that was measured in this study (2.0·105). From five cats living together on a 
farm, the head sample from three remained negative while their paw samples were 
much higher than those from the other two. Still all 15 cats from multiple cat 
households were tested seronegative. 
BISC affected cats served as positive controls. As the Cytobrush samples were taken 
directly from their lesions, high amounts of FdPV2 DNA could be expected. However, 
in none of these samples, more than 200 copies of FdPV2 per GAPDH were 
detected. This was twice the amount of the mean copy number in samples of normal 
skin of seropositive cats. Still, it was seven times less than the mean copy number 
detected in normal skin of seronegative cats. Seroconversion and disease 
development does not seem to be dependent on the virus load alone. This weakens 
once again the hypothesis of a straightforward role of FdPV2 causing BISC. The 
virus might as well be a part of the normal skin flora of cats. The immune system 
would then not produce antibodies against it as long as the skin is intact. The 
seropositive cats were significantly older than the seronegative. Suggesting that older 
cats have had more skin traumas in their lives, this might support this theory. 
However, the two BISC affected cats that served as positive controls in our study 
showed significantly higher amounts of antibodies against FdPV2 than any of the 
“healthy” cats. These observations might imply that active and immunogenic 
replication of FdPV2 precedes the occurrence of BISC, while active replication of the 
same virus is no longer needed for the progression of the disease. However, more 
serum samples of BISC affected cats need to be tested. 
So far, the causative role of FdPV2 in the development of BISC has only been 
supported by repeatedly amplifying FdPV2 DNA from BISC samples. In this study, 
we could detect FdPV2 DNA in normal skin samples of 98% of the investigated cats. 
This proves that the virus is widespread in the cat population, especially among 
healthy cats. However, there is nothing known about the virulence of different FdPV2 
strains nor its general penetration frequency to clinical illness. The Henle-Koch 
postulates have not yet been fulfilled and this may also be difficult in the future, since 
PV cannot be propagated in cell culture to produce a pure stock of inoculating virus. 
Thus, it is still possible that FdPV2 represents just a simple bystander of another yet 
unrecognized causative agens. As we digested the skin samples to extract the DNA, 
we cannot say whether the viral DNA originated from infected skin cells or from virus 
was lying on the surface of the skin. Using IHC to detect viral proteins in full thickness 
skin samples might help to determine the origin of the viral DNA. The limits in 
sensitivity of this technique are described in the beginning of the discussion section. 
In situ hybridization detects viral DNA in skin samples regardless of the replication 
status. Samples taken from BISC and normal skin could be compared. In situ 
hybridization assays using riboprobes might even detect viral RNA and be used to 
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distinguish if the virus is replicating or not. Difficulties in collecting and processing the 
samples give this technique its limits in feasibility. 
Proving the causative role of a virus in the development of a certain disease is very 
challenging. In case of FdPV2, the development of BISC lesions must be proven in 
formerly FdPV2 free cats after infection with the virus. However, this prove is still 
lacking since FdPV2 cannot be propagated in cell culture on one hand and the virus 
is widespread in the healthy cat population on the other hand. Collection of different 
samples (i.e. serum, Cytobrush, full thickness skin biopsies) from the same patient is 
desirable. Multiple tests can be done and the results can be compared. Moreover, 
patients should be sampled repeatedly at different points in time to gain information 
about the interaction of the virus with the cat’s body. Studies with large sample 
population are though needed in order to receive reliable data. This would allow us to 
obtain a better comprehension of the virus’ epidemiology. 
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Appendix 
 
 
Study Primer set BISC Viral plaques SCC ISCC OSCC Other lesions Normal skin 
Kidney et al., 2001 
30
 NO1/NO2      0/50 (0%)  
E5
+
/E5
-
      0/50 (0%)  
IFNR-2/IDNT-2      0/50 (0%)  
Antonsson et al., 2002 
5
 FAP59/FAP64       0/5 (0%) 
Nespeca et al., 2006 
14
 PapF/PapR 1/21 (5%)   0/22 (0%)  0/11 (0%)  
CP4/CP5/PPF1 5/21 (24%)   4/22 (18%)  0/11 (0%)  
Munday et al., 2007 
6
 FAP59/FAP64 11/18 (61%)     0/15 (0%) 0/3 (0%) 
IFNR-2/IDNT-2 9/11 (82%)     0/15 (0%) 0/3 (0%) 
a
 5/18 (28%)       
Munday et al., 2008 
18
 
b
 20/20 (100%)   17/20 (85%)  3/17 (18%)  
Munday et al., 2008 
7
 FAP59/FAP64  2/2 (100%)      
MY09/MY11  2/2 (100%)      
JMPF/JMPR  2/2 (100%)      
Lange et al., 2009 
15
 A16/A37 3/3 (100%)       
Munday et al., 2009 
46
 FAP59/FAP64     1/20 (5%) 0/20 (0%)  
IFNR-2/IDNT-2     0/20 (0%) 0/20 (0%)  
MY09/MY11     0/20 (0%) 0/20 (0%)  
Munday et al., 2009 
22
 FAP59/FAP64   1/1 (100%)     
JMPF/JMPR   1/1 (100%)     
Anis et al., 2010 
8
 
c
 3/3 (100%)   5/5 (100%) 1/1 (100%) 1/1 (100%)  
a
 3/3 (100%)   4/5 (80%)    
Munday et al., 2010 
19
 MY09/MY11       0/44 (0%) 
JMPF/JMPR       34/88 (39%)
d
 
Munday et al., 2010 
20
 MY09/MY11  4/14 (29%)    0/14 (0%)  
FAP59/FAP64  4/14 (29%)    0/14 (0%)  
JMPF/JMPR  14/14 (100%)    1/14 (7%)  
Munday et al., 2010 
31
 MY09/MY11      4/7 (57%) 0/120 (0%) 
jmpSA-F/jmpSA-R      6/7 (86%) 0/120 (0%) 
Study Primer set BISC Viral plaques SCC ISCC OSCC Other lesions Normal skin 
Munday et al., 2011 
23
 MY09/MY11   7/70 (10%)     
JMPF/JMPR   33/70 (48%)     
Munday et al., 2011 
24
 
b
 14/14 (100%) 8/8 (100%)  12/18 (67%)  1/14 (7%)  
34 
 
Study Primer set BISC Viral plaques SCC ISCC OSCC Other lesions Normal skin 
Munday et al., 2011 
47
 FAP59/FAP64     0/30 (0%)   
MY09/MY11     0/30 (0%)   
O’Neill et al., 2011 
9
  
e
 7/22 (32%)   11/74 (15%)  2/12 (17%)  
a
 4/22 (18%)   4/74 (5%)    
Schwittlick et al., 2011 
48
 
b
 1/1 (100%)       
Munday et al., 2013 
3
 FAP59/FAP64 0/1 (0%)       
JMPF/JMPR 0/1 (0%)       
MY09/MY11 1/1 (100%)       
JMY2F/JMY2R 1/1 (100%)       
Dunowska et al., 2014 
13
 FAP59/FAP64      0/1 (0%)  
MY09/MY11      1/1 (100%)  
Unnamed set      1/1 (100%)  
 
Table 6. Rates of reported PV DNA findings in skin samples from cats using PCR. FdPV2 DNA findings are in italic. 
BISC = Bowenoid in situ carcinoma, SCC = squamous cell carcinoma, ISCC = infiltrative squamous cell carcinoma (when defined in study), other lesions = actinic 
keratosis, allergic dermatitis, apocrine gland cyst, apocrine gland cystadenoma, dermatophytosis, dysplasia, eosinophilic granuloma, eosinophilic plaques, feline 
leprosy, fibrosarcoma, glossitis, granulomatous dermatitis, hyperplastic tonsil, hypersensitivity dermatitis, mast cell tumour, melanoma, periodontal disease, 
plasmacytic stomatitis, sarcoids, trichoblastoma, ulcerative gingivitis. 
a sequences later identified by Lange et al. 15, b nested PCR with FAP59/FAP64 and JMPF/JMPR, c HPV1, HPV2, HPV4, 
HPV7, HPV8, HPV10, P1, P6, P8, d equals 23/44 cats (52%), e FAP59/FAP64 and nested PCR with CP65/CP70 and 
CP66/CP69 
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No. Breed Sex Age1 ELISA PCR head PCR paw PCR cat3 
    OD Result Copies2 Result Copies2 Result  
1 Mixed breed Fc 6.9 0.2443 neg. 0.0887 neg. 0.1632 neg. neg. 
2 Mixed breed Mc 6.9 0.1839 neg. 0.0664 neg. 0.1184 neg. neg. 
3 Mixed breed Mc 1.3 0.1854 neg. 0.0117 neg. 0.1880 neg. neg. 
4 Mixed breed Mc 5.0 0.2916 neg. 0.0443 neg. 0.0002 neg. neg. 
5 Mixed breed Mc 17.6 0.2198 neg. 0.0443 neg. 0.0664 neg. neg. 
 
Table 7. Overview of individual data and test results of the negative control cats 
Fc = female castrated, Mc = male castrated 
1
 in years, 
2
 FdPV2 per GAPDH, 
3
 defined as positive when at least 1 PCR sample positive 
 
 
No. Breed Sex Age1 ELISA PCR sample 1 PCR sample 2 PCR cat3 
    OD Result Copies2 Result Copies2 Result  
1 Maine Coon Fc 12.8 2.0406 pos. 165.7712 pos. 13.2511 pos. pos. 
2 Mixed breed Fc 17.0 1.7428 pos. 3.7526 pos. n/a n/a pos. 
 
Table 8. Overview of individual data and test results of the positive control cats 
Fc = female castrated 
1
 in years, 
2
 FdPV2 per GAPDH, 
3
 defined as positive when at least 1 PCR sample positive 
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No. Breed Sex Age1 ELISA PCR head PCR paw PCR cat3 
    OD Result Copies2 Result Copies2 Result  
1 Mixed Breed F 0.8 0.1868 neg. 58.1412 pos. 1.0550 pos. pos. 
2 British Shorthair M 0.5 0.1962 neg. 5.4501 pos. 8.5881 pos. pos. 
3 Mixed Breed F 10.0 0.1899 neg. 46.6417 pos. 38.3712 pos. pos. 
4 Mixed Breed Mc 7.8 0.2183 neg. 78.5387 pos. 61.41055 pos. pos. 
5 Mixed Breed F 0.8 0.1826 neg. 22.5761 pos. 147.1966 pos. pos. 
6 Persian F 12.1 0.5646 pos. 44.9197 pos. 22.5936 pos. pos. 
7 Mixed Breed Mc 3.0 0.2466 neg. 3.2017 pos. 89.1296 pos. pos. 
8 Mixed Breed Mc 11.8 0.7209 pos. 49.3410 pos. 10.7638 pos. pos. 
9 Ocicat Mc 0.9 0.2109 neg. 1.3704 pos. 9.9065 pos. pos. 
10 Persian Fc 1.0 0.2193 neg. 3.5387 pos. 1416.92865 pos. pos. 
11 Mixed Breed Fc 13.8 0.5320 pos. 7.0872 pos. 26.14315 pos. pos. 
12 Mixed Breed Fc 14.0 0.2524 neg. 2.7994 pos. 9.0710 pos. pos. 
13 Bengal F 0.4 0.2659 neg. 2.0334 pos. 4.5716 pos. pos. 
14 Bengal F 0.5 0.2634 neg. 0.7160 pos. 2.7002 pos. pos. 
15 Mixed Breed F n/a 0.2499 neg. 76.1697 pos. 6.7338 pos. pos. 
16 Mixed Breed M n/a 0.2130 neg. 1.2656 pos. 5.4713 pos. pos. 
17 Mixed Breed F n/a 0.2757 neg. 0.1004 neg. 107.0025 pos. pos. 
18 Mixed Breed F n/a 0.2314 neg. 0.0555 neg. 20.5851 pos. pos. 
19 Siamese Fc 13.1 0.2782 neg. 15.8124 pos. 2461.2182 pos. pos. 
20 Mixed Breed F n/a 0.2302 neg. 0.0023 neg. 29.0754 pos. pos. 
21 Mixed Breed Mc 2.6 0.2462 neg. 4.8777 pos. 3.0359 pos. pos. 
22 Mixed Breed Mc 12.0 0.7177 pos. 70.0246 pos. 280.3176 pos. pos. 
23 Mixed Breed M 0.5 0.2113 neg. 12.2588 pos. 10.4068 pos. pos. 
24 Mixed Breed Fc 13.0 0.2255 neg. 0.5141 pos. 2.9148 pos. pos. 
25 Mixed Breed Fc 0.8 0.2036 neg. 47.8899 pos. 33.5388 pos. pos. 
26 Mixed Breed Fc 1.5 0.2376 neg. 21.2677 pos. 19.7329 pos. pos. 
27 Mixed Breed Mc 8.5 0.2244 neg. 1.8758 pos. 3.6419 pos. pos. 
28 Mixed Breed M 0.6 0.2299 neg. 4.3960 pos. 5.1480 pos. pos. 
29 Mixed Breed F 0.6 0.2387 neg. 4.8891 pos. 3.0218 pos. pos. 
30 Mixed Breed M 1.1 0.2365 neg. 3.2924 pos. 374.5652 pos. pos. 
31 Mixed Breed F 0.5 0.3131 neg. 0.0009 neg. 9.7538 pos. pos. 
32 Mixed Breed Fc 4.6 0.2255 neg. 0.1434 neg. 0.5673 pos. pos. 
37 
 
No. Breed Sex Age1 ELISA PCR head PCR paw PCR cat3 
    OD Result Copies2 Result Copies2 Result  
33 Siberian Fc 7.8 0.2529 neg. 2.6556 pos. 5.6988 pos. pos. 
34 NFC x Persian Mc 7.0 0.2469 neg. 0.0396 neg. 1.44975 pos. pos. 
35 Mixed Breed M 0.7 0.1928 neg. 133.11806 n/a 0.3704 pos. pos. 
36 Mixed Breed M 0.3 0.31574 neg. 2.4430 pos. 0.0590 neg. pos. 
37 Mixed Breed F 0.8 1.09384 neg. 18.9307 pos. 56.8713 pos. pos. 
38 Mixed Breed F 0.8 0.2272 neg. 60.8203 pos. 251.54525 pos. pos. 
39 Mixed Breed Mc 3.0 0.2449 neg. 378.3665 pos. 125.3611 pos. pos. 
40 Burmese Mc 13.0 0.4515 pos. 4.5468 pos. 7.7520 pos. pos. 
41 Maine Coon F 0.4 0.52234 neg. 5.8695 pos. 22.4636 pos. pos. 
42 Mixed Breed Mc 2.8 0.3029 neg. 2.6556 pos. 4.1412 pos. pos. 
43 Mixed Breed Fc 11.0 0.2666 neg. 45.3404 pos. 6.9757 pos. pos. 
44 Ragdoll Mc 10.8 0.2091 neg. 2.92385 pos. 1.5408 pos. pos. 
45 Mixed Breed Fc 12.0 0.4538 pos. 59.4657 pos. 71.5011 pos. pos. 
46 NFC M 3.8 0.1898 neg. 17.7842 pos. 1.0824 pos. pos. 
47 Birman M 14.0 0.2120 neg. 0.5642 pos. 4.8362 pos. pos. 
48 Mixed Breed Mc 9.7 0.6321 pos. 0.7166 pos. 0.6067 pos. pos. 
49 Mixed Breed Mc 10.0 0.2043 neg. 1.0674 pos. 3.8258 pos. pos. 
50 Mixed Breed Mc 17.0 0.1763 neg. 0.4111 pos. 8.8936 pos. pos. 
51 Mixed Breed Mc 4.1 0.2149 neg. 0.0055 neg. 1.70035 pos. pos. 
52 Mixed Breed Fc 13.0 0.34984 neg. 27.8191 pos. 418.5231 pos. pos. 
53 Mixed Breed Fc 3.9 0.1975 neg. 391.9568 pos. 39.5821 pos. pos. 
54 Mixed Breed Mc 14.0 0.2544 neg. 620.5154 pos. 54.6866 pos. pos. 
55 Mixed Breed Mc 11.0 0.1780 neg. 2.6495 pos. 0.7194 pos. pos. 
56 Persian F 14.0 0.9130 pos. 1049.3972 pos. 6.3803 pos. pos. 
57 Mixed Breed Fc 11.0 0.2071 neg. 0.2209 pos. 0.8372 pos. pos. 
58 Mixed Breed Mc 3.0 0.1807 neg. 1289.9630 pos. 22.0658 pos. pos. 
59 Mixed Breed Mc 7.0 0.4153 pos. 0.6027 pos. 3.8437 pos. pos. 
60 Burmese Mc 8.1 0.2663 neg. 1.4340 pos. 8.5948 pos. pos. 
61 Mixed Breed Mc 9.0 0.6255 pos. 0.8576 pos. 0.4428 pos. pos. 
62 Mixed Breed Mc 14.9 0.2018 neg. 0.3727 pos. 16.9218 pos. pos. 
63 Mixed Breed F 1.9 0.1881 neg. 9368.4824 pos. 17860.9598 pos. pos. 
64 Mixed Breed Mc 8.0 0.4036 pos. 1.5492 pos. 4.2337 pos. pos. 
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No. Breed Sex Age1 ELISA PCR head PCR paw PCR cat3 
    OD Result Copies2 Result Copies2 Result  
65 Mixed Breed Mc 12.3 0.6086 pos. 90.9880 pos. 181.7245 pos. pos. 
66 Mixed Breed F 1.1 0.2198 neg. 3.2141 pos. 14.5063 pos. pos. 
67 Mixed Breed M 0.8 0.2219 neg. 1.6199 pos. 14.36536 n/a pos. 
68 Mixed Breed Mc n/a 0.8141 pos. 207.8381 pos. 1462.7781 pos. pos. 
69 Mixed Breed Fc 7.0 0.2133 neg. 11.45785 pos. 32.2112 pos. pos. 
70 British Shorthair Mc 4.1 0.2522 neg. 6.8150 pos. 4.0253 pos. pos. 
71 Mixed Breed Mc 16.8 0.3075 neg. 84.5158 pos. 1.3934 pos. pos. 
72 Mixed Breed Mc 12.0 0.2046 neg. 9.8834 pos. 10.9834 pos. pos. 
73 Mixed Breed Mc 0.7 0.2154 neg. 20.6652 pos. 0.2316 pos. pos. 
74 Mixed Breed M n/a 0.2014 neg. 44.2468 pos. 8.2811 pos. pos. 
75 Mixed Breed Mc 3.9 0.2544 neg. 4.4234 pos. 4.2384 pos. pos. 
76 Mixed Breed Mc n/a 0.2436 neg. 0.0320 neg. 3.5802 pos. pos. 
77 Egyptian Mau Fc 8.2 0.5305 pos. 0.3929 pos. 9.0710 pos. pos. 
78 Mixed Breed Mc 17.0 0.1956 neg. 23.8190 pos. 26.2857 pos. pos. 
79 Mixed Breed M 0.7 0.1991 neg. 21.1195 pos. 0.0313 neg. pos. 
80 Mixed Breed M 0.7 0.2017 neg. 29.8767 pos. 202664.0048 pos. pos. 
81 British Shorthair Mc 8.0 0.4730 pos. 2.8990 pos. 5.5140 pos. pos. 
82 Siberian F 6.3 0.32344 neg. 132.8222 pos. 157.7321 pos. pos. 
83 Mixed Breed Mc 10.1 0.2095 neg. 16.2059 pos. 3.9656 pos. pos. 
84 Mixed Breed Mc 9.3 0.1939 neg. 0.2246 pos. 2.5905 pos. pos. 
85 Maine Coon Mc 12.3 0.3399 pos. 0.0004 neg. 12.2418 pos. pos. 
86 Mixed Breed Mc 10.1 0.1565 neg. 0.0380 neg. 1.0258 pos. pos. 
87 Mixed Breed Mc 5.1 0.1591 neg. 0.4531 pos. 5.0756 pos. pos. 
88 Mixed Breed M n/a 0.4017 pos. 135.5546 pos. 27.8022 pos. pos. 
89 Mixed Breed Mc n/a 0.4039 pos. 0.2997 pos. 14.36536 n/a pos. 
90 Mixed Breed Mc 7.0 0.1911 neg. 0.0034 neg. 0.2150 pos. pos. 
91 Mixed Breed Mc 13.0 0.2726 neg. 34.7049 pos. 1.2834 pos. pos. 
92 Mixed Breed Fc 4.8 0.1929 neg. 9.7235 pos. 0.0272 neg. pos. 
92 Mixed Breed Mc 9.8 0.1820 neg. 3.9441 pos. 0.0059 neg. pos. 
94 Mixed Breed Fc 9.1 0.2363 neg. 61.5809 pos. 4.3892 pos. pos. 
95 Siamese Fc 14.2 0.2644 neg. 0.0099 neg. 0.0138 neg. neg. 
96 Persian M 4.6 0.2626 neg. 0.3797 pos. 0.6535 pos. pos. 
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No. Breed Sex Age1 ELISA PCR head PCR paw PCR cat3 
    OD Result Copies2 Result Copies2 Result  
97 Mixed Breed F 0.3 0.1539 neg. 0.1094 neg. 0.0893 neg. neg. 
98 Turkish Van M 0.4 0.1539 neg. 1.1300 pos. 1.6728 pos. pos. 
99 Mixed Breed Fc 15.3 0.6067 pos. 8.5867 pos. 0.02385 neg. pos. 
100 Mixed Breed Mc 11.8 0.2233 neg. 0.3238 pos. 0.2740 pos. pos. 
 
Table 9. Overview of individual data and test results of the sample population 
NFC = Norwegian forest cat, F = female, Fc = female castrated, M = male, Mc = male castrated 
1
 in years, 
2
 FdPV2 per GAPDH, 
3
 defined as positive when at least 1 PCR sample positive, 
4
 reaction against GST (see discussion), 
5
 2
 
 products after 
amplification (see results), 
6
 negative for GAPDH (see results) 
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Figure 6. Boxplots of FdPV2 ELISA OD values from cats divided into subsets based on age (A), breed (B) or sex (C). For the 
definition of the age groups, cats were divided into 10 categories each spanning approximately 1.7 years. The categories for sex 
were abbreviated as F, Fc, M and Mc for female, female castrated, male and male castrated, respectively. The numbers of the 
individual group sizes are indicated on top of the graphs. 
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